Skip to content
AnalystLens

Leidos Holdings 8-K Report, Financial Results (Nov 4, 2025)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed November 4, 2025
Period End
November 4, 2025
Security
LDOS
In the record · 2016–202610-K1210-Q338-K130

LDOS filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 130 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Aug ’17Aug ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Leadership change8-K · Feb ’22Feb ’22
  4. Material agreement8-K · Oct ’26Oct ’26

Summary

Summary of the 8-K filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.

Leidos Holdings, Inc. (NYSE: LDOS) reported results for the third fiscal quarter ended October 3, 2025, in a press release furnished as Exhibit 99.1 to this Form 8-K.

Revenues were $4,469 milliona, up 7% year-over-year (6% organic), and net income was $369 million, or $2.82 per diluted share. Adjusted EBITDA was $616 million with a 13.8% margin, down from 14.2% a year earlier, and non-GAAP diluted EPS was $3.05, up 4% year-over-year. Operating cash flow was $711 million and non-GAAP free cash flow was $680 million.

Net bookings were $5.9 billionb for a book-to-bill ratio of 1.3, and total backlog reached $47.7 billion, up 5% year-over-year, of which $9.1 billion was funded. Notable awards included a $2.2 billion, seven-year classified mission support contract in the intelligence community and a $760 million NASA Human Health and Performance IDIQ subcontract. Management cited the U.S. government shutdown as a factor but raised its fiscal 2025 adjusted EBITDA margin guidance to high 13% (from mid 13%) and non-GAAP diluted EPS guidance to $11.45–$11.75 (from $11.15–$11.45), while holding revenue guidance at $17.00–$17.25 billion and operating cash flow guidance at approximately $1.65 billion.

The company ended the quarter with $974 millionc in cash and cash equivalents and $4.7 billion of debt, after $450 million in term loan principal payments and $153 million returned to shareholders. On October 31, 2025, the board declared a quarterly dividend of $0.43 per share, payable December 31, 2025.

Key Highlights

  1. Q3 FY2025 revenues of $4,469 million, up 7% year-over-year, including 6% organic growth
  2. Net income of $369 million, or $2.82 per diluted share; non-GAAP diluted EPS of $3.05, up 4% year-over-year
  3. Adjusted EBITDA of $616 million with a 13.8% margin, versus 14.2% in the prior-year quarter; the filing notes a $24 million increase to legal reserves in the quarter
  4. Net bookings of $5.9 billion, book-to-bill ratio of 1.3, and total backlog of $47.7 billion (up 5% year-over-year)
  5. Fiscal 2025 guidance raised for adjusted EBITDA margin (high 13%) and non-GAAP diluted EPS ($11.45–$11.75); revenue and operating cash flow guidance unchanged
  6. Operating cash flow of $711 million and non-GAAP free cash flow of $680 million in the quarter
  7. Quarterly dividend increased to $0.43 per share, declared October 31, 2025, payable December 31, 2025

Frequently Asked Questions

  1. How did Leidos perform financially in the third quarter of fiscal 2025?

    Revenues rose 7% year-over-year to $4,469 million, with 6% organic growth. Net income was $369 million, or $2.82 per diluted share, and non-GAAP diluted EPS was $3.05, up 4%. Adjusted EBITDA margin declined to 13.8% from 14.2%.

  2. Did Leidos change its full-year fiscal 2025 guidance?

    Partially. Management raised its adjusted EBITDA margin guidance to high 13% from mid 13% and its non-GAAP diluted EPS guidance to $11.45–$11.75 from $11.15–$11.45. Revenue guidance of $17.00–$17.25 billion and operating cash flow guidance of approximately $1.65 billion were unchanged.

  3. What were the major contract awards and how large is the backlog?

    Net bookings were $5.9 billion in the quarter, with a book-to-bill ratio of 1.3. Total backlog was $47.7 billion, of which $9.1 billion was funded. Notable awards included a $2.2 billion seven-year classified intelligence community mission support contract, a $760 million NASA Human Health and Performance IDIQ subcontract, and a $540 million seven-year counterterrorism software and IT support contract.

  4. How strong is Leidos's balance sheet and cash position?

    As of October 3, 2025, Leidos had $974 million in cash and cash equivalents and $4.7 billion of debt. During the quarter it made $450 million in term loan principal payments and returned $153 million to shareholders, including $102 million in share repurchases and $51 million in dividends.

  5. What is the company's dividend and how did management describe the environment?

    The board declared a cash dividend of $0.43 per share on October 31, 2025, an increase of 7.5% over the prior quarter's dividend, payable December 31, 2025 to holders of record on December 15, 2025. The CEO said results were achieved despite the government shutdown and expressed optimism about alignment with administration priorities.